Alecta Tjanstepension Omsesidigt Buys 110,300 Shares of AbbVie Inc. $ABBV

Alecta Tjanstepension Omsesidigt grew its stake in shares of AbbVie Inc. (NYSE:ABBV) by 10.5% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,158,900 shares of the company’s stock after acquiring an additional 110,300 shares during the period. AbbVie comprises approximately 1.2% of Alecta Tjanstepension Omsesidigt’s investment portfolio, making the stock its 27th biggest holding. Alecta Tjanstepension Omsesidigt owned approximately 0.07% of AbbVie worth $268,262,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of ABBV. Chelsea Counsel Co. bought a new stake in shares of AbbVie in the 3rd quarter valued at about $26,000. Texas Capital Bancshares Inc TX bought a new position in shares of AbbVie during the third quarter valued at approximately $31,000. Evolution Wealth Management Inc. purchased a new position in AbbVie during the second quarter valued at approximately $26,000. Caitlin John LLC purchased a new position in AbbVie during the third quarter valued at approximately $33,000. Finally, Redmont Wealth Advisors LLC bought a new position in AbbVie in the third quarter worth approximately $41,000. Institutional investors own 70.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ABBV shares. Barclays began coverage on AbbVie in a report on Thursday, February 19th. They set an “overweight” rating and a $275.00 target price for the company. William Blair reissued an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Guggenheim restated a “buy” rating on shares of AbbVie in a research note on Thursday, March 12th. Piper Sandler raised their price objective on AbbVie from $289.00 to $299.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Finally, Evercore cut their target price on AbbVie from $232.00 to $228.00 and set an “outperform” rating on the stock in a research note on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, AbbVie currently has a consensus rating of “Moderate Buy” and an average target price of $253.15.

Insiders Place Their Bets

In other news, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company’s stock, valued at approximately $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Perry C. Siatis sold 22,381 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the completion of the transaction, the executive vice president owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.25% of the stock is owned by insiders.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics (an AbbVie unit) released new global consumer research and updated educational programs that could support its aesthetics franchise and long‑term revenue diversification. Allergan Aesthetics Reveals Evolution in Approach to Modern Aesthetic Treatments
• Neutral Sentiment: Independent valuation and market‑commentary pieces highlight a recent share‑price pullback and renewed debate over AbbVie’s near‑term multiple; these analyses may lead to more analyst revisions but are not a direct operational hit. Assessing AbbVie (ABBV) Valuation After The Recent Share Price Pullback
• Negative Sentiment: FDA approved J&J’s Icotyde, the first oral IL‑23 inhibitor, creating direct competition for Skyrizi; analysts and articles warn Icotyde could capture significant market share because of oral dosing convenience, pressuring AbbVie’s key growth driver. J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
• Negative Sentiment: Market reaction: multiple outlets report a ~5% intraday drop and continued underperformance vs. peers as investors price in Icotyde competition and reassess AbbVie’s growth outlook. Elevated volume suggests defensive positioning. ABBV Stock Slides 5%: Is J&J’s Icotyde a Threat to Skyrizi?
• Negative Sentiment: Breckenridge launched a generic version of Savella (milnacipran), which introduces additional generic competition in a product AbbVie previously marketed—incremental revenue headwind for that niche pain product. Breckenridge announces launch of Milnacipran HCl Tablets, generic equivalent of Savella®

AbbVie Trading Down 1.0%

Shares of ABBV opened at $206.32 on Friday. The firm has a market cap of $364.80 billion, a PE ratio of 87.42, a P/E/G ratio of 0.72 and a beta of 0.34. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a fifty day moving average price of $223.41 and a 200-day moving average price of $224.71.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 1,579.75% and a net margin of 6.91%.The business had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter in the previous year, the firm earned $2.16 earnings per share. The company’s revenue was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, research analysts forecast that AbbVie Inc. will post 12.31 EPS for the current year.

AbbVie Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.4%. The ex-dividend date is Wednesday, April 15th. AbbVie’s payout ratio is presently 293.22%.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.